Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 4/20 | 0.40 |
| ▸ | ACACA | Q13085 | 3/20 | 0.40 |
| ▸ | IL1B | P01584 | 5/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 3/20 | 0.38 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13323798 | 0.88 | SMN1; SMN2 (0.43) | ACACBACACACA1CA2KDM4E | |
| SCHEMBL2151051 | 0.85 | KDM1A (0.42) | IL1BP2RX7KDM1ARCOR1CA1 | |
| SCHEMBL1710895 | 0.82 | ACACB (0.35) | ACACBACACAIL1BP2RX7DDB1 | |
| SCHEMBL15576261 | 0.82 | HTR2B (0.44) | IL1BP2RX7KDM1ARCOR1ROCK2 | |
| SCHEMBL1710702 | 0.81 | CA2 (0.40) | ACACBACACAIL1BP2RX7KDM1A | |
| SCHEMBL2167617 | 0.81 | IL1B (0.39) | ACACBACACAIL1BP2RX7DDB1 | |
| SCHEMBL3125056 | 0.81 | MEN1 (0.44) | CA1CA2 | |
| SCHEMBL2151175 | 0.81 | KDM1A (0.41) | IL1BP2RX7KDM1ARCOR1CA1 | |
| SCHEMBL3128178 | 0.79 | USP30 (0.39) | ACACBACACADDB1CRBNKDM1A | |
| SCHEMBL2178511 | 0.79 | CA1 (0.40) | DDB1CRBNCA1CA2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145198-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-05-26 | — | — | US | disclosed |
| US-9193669-B2 | Compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20140228443-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-8674137-B2 | Compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20100113539-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113539-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, ALDH1A2 | ACACB 325/4885ACACA 541/4885IL1B 3449/4885 |
| US-20160145198-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, ALDH1A2 | ACACB 325/4885ACACA 541/4885IL1B 3449/4885 |
| US-20140228443-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, ALDH1A2 | ACACB 325/4885ACACA 541/4885IL1B 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.